APVO News and Press, Aptevo Therapeutics Inc. From 06/10/20

New Preclinical Data Show That ALG.APV-527 has Potential for a Favorable Safety Profile Does Not Induce Systemic T-cell Activation at High Doses Which Were Observed in a Urelumab Analogue in a Side-by-Side Comparison ALG.APV-527 is a Novel Immunotherapeutic Bispecific Candidate...

Advances Phase 1/1b Clinical Trial of APVO436 for the Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome; Cohort 6 Enrollment Ongoing Reports Preliminary Evidence of a Potential Clinical Response Observed with APVO436 Sharpens Focus on Novel ADAPTI...

SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The N...

Aptevo Therapeutics (NASDAQ: APVO ): FY GAAP EPS of -$1.09 beats by $0.04 . More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Advances Dose-Escalation Phase 1/1b Study of APVO436 for Treatment of Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome Reports Preliminary Evidence of Clinical Activity of APVO436; Dosing in Cohort 6 to Begin Shortly Achieves Record Annual IXINITY ® Net Reve...

Trial Advancing on Schedule with Dosing in Cohort 6 Set to Begin Shortly; Dose Levels Now Entering Potential Therapeutic Range No Evidence of Dose-Limiting Toxicities Observed in Cohort 5 No Evidence of Drug-Induced Anti-Drug Antibodies Observed to Date SEATTLE, WA / ACCESS...

Transforms Aptevo into a ‘Pure Play' Biotechnology Company Focused on the Development of Proprietary ADAPTIR™ Bispecific Antibody Therapeutics Strengthens Aptevo's Financial Position; Eliminates MidCap Debt Obligation; Provides Immediate Non-Dilutive Capital Extending ...

Acquisition Expected to be Immediately Accretive to Adjusted EBITDA 1 Announces US$20 Million Credit Facility with MidCap Financial TORONTO and CHICAGO and MONTREAL, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“ Medexus ” or the “ Company &...

APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead Sciences, Takeda Oncology, Agios Pharmaceuticals, Astellas Pharma and Boehringer Ingelhei...

SEATTLE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to APVO...